Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Colorectal Neoplasms

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 84 articles: HTML format Text format

Single Articles

January 2012
1. SOUGLAKOS J , Ziras N, Kakolyris S, Boukovinas I, et al
   Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
   Br J Cancer. 2012 Jan 12. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. DOTAN E , Meropol NJ, Zhu F, Zambito F, et al
   Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer.
   Br J Cancer. 2012 Jan 12. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. JEHN CF , Boning L, Kroning H, Possinger K, et al
   Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer.
   Br J Cancer. 2012 Jan 3. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
4. CARLSSON E , Ranki A, Sipila L, Karenko L, et al
   Potential role of a navigator gene NAV3 in colorectal cancer.
   Br J Cancer. 2011 Dec 15. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. PARKIN DM
   9. Cancers attributable to inadequate physical exercise in the UK in 2010.
   Br J Cancer. 2011;105 Suppl 2:S38-41.
   PubMed     Text format     Related articles   
   
   
   
   
6. PARKIN DM , Boyd L
   6. Cancers attributable to dietary factors in the UK in 2010. III. Low consumption of fibre.
   Br J Cancer. 2011;105 Suppl 2:S27-30.
   PubMed     Text format     Related articles   
   
   
   
   
7. PARKIN DM
   5. Cancers attributable to dietary factors in the UK in 2010. II. Meat consumption.
   Br J Cancer. 2011;105 Suppl 2:S24-26.
   PubMed     Text format     Related articles   
   
   
   
   November 2011
8. KABAT GC , Kim MY, Strickler HD, Shikany JM, et al
   A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women.
   Br J Cancer. 2011 Nov 29. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. ZEESTRATEN EC , Maak M, Shibayama M, Schuster T, et al
   Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer.
   Br J Cancer. 2011 Nov 22. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. GILBERT DC , Chalmers AJ, El-Khamisy SF
    Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets.
    Br J Cancer. 2011 Nov 22. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. FERDINANDE L , Decaestecker C, Verset L, Mathieu A, et al
    Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer.
    Br J Cancer. 2011 Nov 22. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. TSUJI S , Midorikawa Y, Takahashi T, Yagi K, et al
    Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis.
    Br J Cancer. 2011 Nov 17. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. DAVIES NJ , Batehup L, Thomas R
    The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature.
    Br J Cancer. 2011;105 Suppl 1:S52-73.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. KHAN NF , Mant D, Carpenter L, Forman D, et al
    Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study.
    Br J Cancer. 2011;105 Suppl 1:S29-37.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. GORMLEY JA , Hegarty SM, O'Grady A, Stevenson MR, et al
    The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study.
    Br J Cancer. 2011;105:1487-94.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. BOSE D , Zimmerman LJ, Pierobon M, Petricoin E, et al
    Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells.
    Br J Cancer. 2011 Nov 1. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
17. KANAI M , Ishiguro H, Mori Y, Kitano T, et al
    Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer.
    Br J Cancer. 2011 Oct 27. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. MELICHAR B , Casado E, Bridgewater J, Bennouna J, et al
    Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial.
    Br J Cancer. 2011 Oct 25. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. BUCZACKI S , Davies RJ, Winton DJ
    Stem cells, quiescence and rectal carcinoma: an unexplored relationship and potential therapeutic target.
    Br J Cancer. 2011;105:1253-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. BENNETT L , Zhao Z, Barber B, Zhou X, et al
    Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment.
    Br J Cancer. 2011 Oct 11. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. SKOG M , Bono P, Lundin M, Lundin J, et al
    Expression and prognostic value of transcription factor PROX1 in colorectal cancer.
    Br J Cancer. 2011 Oct 4. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
22. WHITE ID , Allan H, Faithfull S
    Assessment of treatment-induced female sexual morbidity in oncology: is this a part of routine medical follow-up after radical pelvic radiotherapy?
    Br J Cancer. 2011;105:903-10.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. BAADE PD , Dasgupta P, Aitken J, Turrell G, et al
    Geographic remoteness and risk of advanced colorectal cancer at diagnosis in Queensland: a multilevel study.
    Br J Cancer. 2011 Sep 6. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
24. JANSEN L , Hoffmeister M, Chang-Claude J, Brenner H, et al
    Benefit finding and post-traumatic growth in long-term colorectal cancer survivors: prevalence, determinants, and associations with quality of life.
    Br J Cancer. 2011 Aug 30. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. GORNICK MC , Rennert G, Moreno V, Gruber SB, et al
    Adiponectin gene and risk of colorectal cancer.
    Br J Cancer. 2011;105:562-4.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. HEWITSON P , Ward AM, Heneghan C, Halloran SP, et al
    Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial.
    Br J Cancer. 2011;105:475-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. LARSSON A , Johansson ME, Wangefjord S, Gaber A, et al
    Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.
    Br J Cancer. 2011 Aug 9. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. DAY FL , Link E, Ngan S, Leong T, et al
    FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy.
    Br J Cancer. 2011;105:498-504.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. ABULI A , Fernandez-Rozadilla C, Giraldez MD, Munoz J, et al
    A two-phase case-control study for colorectal cancer genetic susceptibility: candidate genes from chromosomal regions 9q22 and 3q22.
    Br J Cancer. 2011 Aug 2. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
30. VINOGRADOVA Y , Coupland C, Hippisley-Cox J
    Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies.
    Br J Cancer. 2011;105:452-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. BANDO H , Yoshino T, Tsuchihara K, Ogasawara N, et al
    KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab.
    Br J Cancer. 2011;105:403-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. BIRKENKAMP-DEMTRODER K , Maghnouj A, Mansilla F, Thorsen K, et al
    Repression of KIAA1199 attenuates Wnt-signalling and decreases the proliferation of colon cancer cells.
    Br J Cancer. 2011 Jul 19. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. STINTZING S , Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, et al
    Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
    Br J Cancer. 2011;105:206-11.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. WEIDLICH S , Walsh K, Crowther D, Burczynski ME, et al
    Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours.
    Br J Cancer. 2011;105:246-54.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. MEAD R , Duku M, Bhandari P, Cree IA, et al
    Circulating tumour markers can define patients with normal colons, benign polyps, and cancers.
    Br J Cancer. 2011;105:239-45.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
36. O'CONNOR JP , Rose CJ, Jackson A, Watson Y, et al
    DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6.
    Br J Cancer. 2011;105:139-45.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. MIRZA KA , Wyke SM, Tisdale MJ
    Attenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF).
    Br J Cancer. 2011;105:83-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. ALGARS A , Lintunen M, Carpen O, Ristamaki R, et al
    EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer.
    Br J Cancer. 2011 Jun 21. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. LIN L , Liu Y, Li H, Li PK, et al
    Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030.
    Br J Cancer. 2011 Jun 21. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. CASSIDY J , Clarke S, Diaz-Rubio E, Scheithauer W, et al
    XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
    Br J Cancer. 2011 Jun 14. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. BRUIN SC , He Y, Mikolajewska-Hanclich I, Liefers GJ, et al
    Molecular alterations associated with liver metastases development in colorectal cancer patients.
    Br J Cancer. 2011 Jun 14. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. TORRING ML , Frydenberg M, Hansen RP, Olesen F, et al
    Time to diagnosis and mortality in colorectal cancer: a cohort study in primary care.
    Br J Cancer. 2011;104:1930.
    PubMed     Text format     Related articles   
    
    
    
    
43. MARCUELLO E , Paez D, Pare L, Salazar J, et al
    A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
    Br J Cancer. 2011 Jun 7. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
44. CRONIN-FENTON DP , Riis AH, Lash TL, Dalton SO, et al
    Antidepressant use and colorectal cancer risk: a Danish population-based case-control study.
    Br J Cancer. 2011;104:1804.
    PubMed     Text format     Related articles   
    
    
    
    
45. KALIMUTHO M , Di Cecilia S, Del Vecchio Blanco G, Roviello F, et al
    Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer.
    Br J Cancer. 2011;104:1770-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. WANG J , Zhao Z, Barber B, Sherrill B, et al
    A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. HAUG U , Kuntz KM, Knudsen AB, Hundt S, et al
    Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia.
    Br J Cancer. 2011;104:1779-85.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. RAWSON JB , Mrkonjic M, Daftary D, Dicks E, et al
    Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. OLIPHANT R , Brewster DH, Morrison DS
    The changing association between socioeconomic circumstances and the incidence of colorectal cancer: a population-based study.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. SCARTOZZI M , Bearzi I, Mandolesi A, Giampieri R, et al
    Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. GRAY NM , Hall SJ, Browne S, Macleod U, et al
    Modifiable and fixed factors predicting quality of life in people with colorectal cancer.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. WIN AK , Dowty JG, English DR, Campbell PT, et al
    Body mass index in early adulthood and colorectal cancer risk for carriers and non-carriers of germline mutations in DNA mismatch repair genes.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
53. VALLE L , Capella G, Moreno VR, Rennert G, et al
    Reply: Allelic imbalance of TGFBR1 is not a major contributor to the genetic predisposition to colorectal cancer.
    Br J Cancer. 2011;104:1519-20.
    PubMed     Text format     Related articles   
    
    
    
    
54. ABADIE C , Killian A, Tinat J, Bougeard M, et al
    Allelic imbalance of the TGFbetaR1 is not a major contributor to the genetic predisposition to colorectal cancer.
    Br J Cancer. 2011;104:1517-8.
    PubMed     Text format     Related articles   
    
    
    
    
55. STECKER K , Vieth M, Koschel A, Wiedenmann B, et al
    Impact of the coxsackievirus and adenovirus receptor on the adenoma-carcinoma sequence of colon cancer.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. WALLIN U , Glimelius B, Jirstrom K, Darmanis S, et al
    Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
57. CHUA W , Charles KA, Baracos VE, Clarke SJ, et al
    Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
58. FLATMARK K , Borgen E, Nesland JM, Rasmussen H, et al
    Disseminated tumour cells as a prognostic biomarker in colorectal cancer.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
59. BHANDARI S , Sinha A, Clark SK
    Evaluation of management of desmoids tumours associated with familial adenomatous polyposis in Dutch patients.
    Br J Cancer. 2011;104:1236.
    PubMed     Text format     Related articles   
    
    
    
    
60. FAN F , Samuel S, Gaur P, Lu J, et al
    Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. LOUPAKIS F , Cremolini C, Fioravanti A, Orlandi P, et al
    Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
62. SULLIVAN-GUNN M , Hinch E, Vaughan V, Lewandowski P, et al
    Choosing a stable housekeeping gene and protein is essential in generating valid gene and protein expression results.
    Br J Cancer. 2011;104:1055.
    PubMed     Text format     Related articles   
    
    
    
    
63. FIORENTINO F , Vasilakis C, Treasure T
    Clinical reports of pulmonary metastasectomy for colorectal cancer: a citation network analysis.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
64. BERTOLINI F , Malavasi N, Scarabelli L, Fiocchi F, et al
    FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
65. DONG Y , Wu WK, Wu CW, Sung JJ, et al
    MicroRNA dysregulation in colorectal cancer: a clinical perspective.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
66. TORRING ML , Frydenberg M, Hansen RP, Olesen F, et al
    Time to diagnosis and mortality in colorectal cancer: a cohort study in primary care.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
67. WONG SC , Ng SS, Cheung MT, Luk LY, et al
    Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
68. CUI T , Chen Y, Yang L, Knosel T, et al
    DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
69. KNIJN N , Mekenkamp LJ, Klomp M, Vink-Borger ME, et al
    KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
70. WOLIN KY , Yan Y, Colditz GA
    Physical activity and risk of colon adenoma: a meta-analysis.
    Br J Cancer. 2011;104:882-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
71. NORGAARD M , Farkas DK, Pedersen L, Erichsen R, et al
    Irritable bowel syndrome and risk of colorectal cancer: a Danish nationwide cohort study.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
72. LU CY , Uen YH, Tsai HL, Chuang SC, et al
    Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
73. MOLE DJ , O'Neill C, Hamilton P, Olabi B, et al
    Expression of osteopontin coregulators in primary colorectal cancer and associated liver metastases.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
74. AZZARITI A , Bocci G, Porcelli L, Fioravanti A, et al
    Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
75. COGHILL AE , Newcomb PA, Chia VM, Zheng Y, et al
    Pre-diagnostic NSAID use but not hormone therapy is associated with improved colorectal cancer survival in women.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
76. OSTERLUND P , Soveri LM, Isoniemi H, Poussa T, et al
    Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
77. YOKOTA T , Ura T, Shibata N, Takahari D, et al
    BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
78. OLADIPO O , Conlon S, O'Grady A, Purcell C, et al
    The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue.
    Br J Cancer. 2011;104:480-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
79. SEGUI N , Stevens KN, Guino E, Rozek LS, et al
    No association between germline allele-specific expression of TGFBR1 and colorectal cancer risk in Caucasian and Ashkenazi populations.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
80. MOLINA-GARRIDO MJ , Guillen-Ponce C
    Comment on 'capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer'.
    Br J Cancer. 2011;104:224-5.
    PubMed     Text format     Related articles   
    
    
    
    
81. WATANABE T , Semba S, Yokozaki H
    Regulation of PTEN expression by the SWI/SNF chromatin-remodelling protein BRG1 in human colorectal carcinoma cells.
    Br J Cancer. 2011;104:146-54.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
82. NIEUWENHUIS MH , Mathus-Vliegen EM, Baeten CG, Nagengast FM, et al
    Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients.
    Br J Cancer. 2011;104:37-42.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
83. GOLDENRING JR , Nam KT
    Rab25 as a tumour suppressor in colon carcinogenesis.
    Br J Cancer. 2011;104:33-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
84. GARUFI C , Torsello A, Tumolo S, Ettorre GM, et al
    Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
    Br J Cancer. 2010;103:1542-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: